Publications by authors named "N Liguori"

Cyanobacteria were the first microorganisms that released oxygen into the atmosphere billions of years ago. To do it safely under intense sunlight, they developed strategies that prevent photooxidation in the photosynthetic membrane, by regulating the light-harvesting activity of their antenna complexes-the phycobilisomes-via the orange-carotenoid protein (OCP). This water-soluble protein interacts with the phycobilisomes and triggers nonphotochemical quenching (NPQ), a mechanism that safely dissipates overexcitation in the membrane.

View Article and Find Full Text PDF

Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is to evaluate the choice of DMTs in pwMS older than 50 years old in a real-world setting.

Methods: Cross-sectional study of pwMS from the Argentine MS and NMOSD Registry.

View Article and Find Full Text PDF

Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or after platinum-based chemotherapy and is currently undergoing clinical trials in a variety of tumor types.

View Article and Find Full Text PDF

The antenna complexes of Photosystem I present low-lying states visible as red-shifted and broadened absorption and fluorescence bands. Among these, Lhca4 has the most evident features of these "red" states, with a fluorescence band shifted by more than 25 nm from typical LHC emission. This signal arises from a mixing of exciton and charge-transfer (CT) states within the excitonically coupled a603-a609 chlorophyll (Chl) dimer.

View Article and Find Full Text PDF
Article Synopsis
  • Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are classified by their effectiveness, with high-efficacy treatments (HETs) having limited data in Latin America, particularly Argentina.
  • A study using the RelevarEM registry found that 19% of 2,450 patients with relapsing-remitting MS (RRMS) were on HETs, with many switching due to treatment failures, leading to a significant increase in HET usage from 11.65% to 29.55% over two time periods.
  • The research highlighted rapid growth in HET adoption, with the most common treatments being alemtuzumab and cladribine, and emphasized understanding the demographics
View Article and Find Full Text PDF